| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:917.)
© 2001 American Heart Association, Inc.
Original Contributions |
C-Reactive Protein in Ischemic Stroke
An Independent Prognostic Factor
From the Department of Neurology and Neurorehabilitation, Casa di Cura Villa Pini d’Abruzzo, Chieti, Italy.
Correspondence to Dr Mario Di Napoli, MD, Department of Neurology and Neurorehabilitation, Casa di Cura Villa Pini d’Abruzzo, Via dei Frentani, 228, 66100-Chieti, Italy. E-mail mariodinapoli{at}katamail.com
Background and Purpose—There is growing evidence of the prognostic importance of C-reactive protein (CRP) in ischemic stroke. However, the independent value of CRP at different stages after stroke has not been established. Therefore, we assessed the prognostic values of CRP in ischemic stroke. We also compared the relation of CRP at admission and discharge with 1-year outcome.
Methods—One hundred ninety-three patients were included in a derivation set (n=128) and a validation set (n=65). Serum CRP was measured, within 24 hours after index ischemic stroke, within 48 to 72 hours, and at hospital discharge. We examined the association between the level of CRP at different stages after stroke and outcome. We adjusted for the possible confounding effect using a multivariate Cox proportional hazard model.
Results—A cutoff point of 1.5 mg/dL for CRP at discharge provided optimum sensitivity and specificity for adverse outcome, based on the receiver operator curves. CRP at admission (hazard ratio [HR] 2.78, 95% CI 1.45 to 5.33; P=0.0021) and discharge (HR 9.42, 95% CI 4.27 to 19.05; P<0.0001) were predictors of the combined end point of new vascular events or death at 1 year. CRP at hospital discharge was the strongest independent marker of adverse outcome (HR 7.42, 95% CI 2.75 to 20.03; P=0.0001). These results were confirmed in the validation set (HR 15.66, 95% CI 3.36 to 72.97; P=0.0005).
Conclusions—CRP is a marker of increased 1-year risk in ischemic stroke. CRP at discharge is better related to later outcome and could be of greater utility for risk stratification. These findings are consistent with the hypothesis that elevated CRP may predict future cardiovascular events or death.
Key Words: inflammation • prognosis • proteins • stroke outcome • stroke, ischemic
This article has been cited by other articles:
 |
|
 |
|
  W. Whiteley, W. L. Chong, A. Sengupta, and P. Sandercock Blood Markers for the Prognosis of Ischemic Stroke: A Systematic Review Stroke, May 1, 2009; 40(5): e380 - e389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli and P. Singh Is Plasma Fibrinogen Useful in Evaluating Ischemic Stroke Patients?: Why, How, and When Stroke, May 1, 2009; 40(5): 1549 - 1552. [Full Text] [PDF]
|
|
|
|
|
|
S. Shantikumar, P. J. Grant, A. J. Catto, J. M. Bamford, and A. M. Carter Elevated C-Reactive Protein and Long-Term Mortality After Ischaemic Stroke: Relationship With Markers of Endothelial Cell and Platelet Activation Stroke, March 1, 2009; 40(3): 977 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Norja, L. Nuutila, P. J Karhunen, and S. Goebeler C-reactive protein in vulnerable coronary plaques J. Clin. Pathol., May 1, 2007; 60(5): 545 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Carty, P. Heagerty, K. Nakayama, E. C. McClung, J. Lewis, D. Lum, E. Boespflug, C. McCloud-Gehring, B. R. Soleimani, J. Ranchalis, et al. Inflammatory Response After Influenza Vaccination in Men With and Without Carotid Artery Disease Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2738 - 2744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Kobeissy, A. K. Ottens, Z. Zhang, M. C. Liu, N. D. Denslow, J. R. Dave, F. C. Tortella, R. L. Hayes, and K. K. W. Wang Novel Differential Neuroproteomics Analysis of Traumatic Brain Injury in Rats Mol. Cell. Proteomics, October 1, 2006; 5(10): 1887 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Montaner, I. Fernandez-Cadenas, C. A. Molina, M. Ribo, R. Huertas, A. Rosell, A. Penalba, L. Ortega, P. Chacon, and J. Alvarez-Sabin Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis Stroke, May 1, 2006; 37(5): 1205 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Kirshner, J. Biller, and A. S. Callahan III Long-Term Therapy to Prevent Stroke J Am Board Fam Med, November 1, 2005; 18(6): 528 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K.S. Craft, E. R. Glasper, L. McCullough, N. Zhang, N. Sugo, T. Otsuka, P. D. Hurn, and A. C. DeVries Social Interaction Improves Experimental Stroke Outcome Stroke, September 1, 2005; 36(9): 2006 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Kiortsis, S. Tsouli, E. S. Lourida, V. Xydis, M. I. Argyropoulou, M. Elisaf, and A. D. Tselepis Lack of Association Between Carotid Intima-Media Thickness and PAF-Acetylhydrolase Mass and Activity in Patients with Primary Hyperlipidemia Angiology, July 1, 2005; 56(4): 451 - 458. [Abstract] [PDF]
|
|
|
|
|
|
M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al. Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members Stroke, June 1, 2005; 36(6): 1316 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurth, J. M. Gaziano, K. M. Rexrode, C. S. Kase, N. R. Cook, J. E. Manson, and J. E. Buring Prospective Study of Body Mass Index and Risk of Stroke in Apparently Healthy Women Circulation, April 19, 2005; 111(15): 1992 - 1998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Wang, X. Zhu, Q. Xu, X. Ding, Y. E. Chen, and Q. Song Effect of C-reactive protein on gene expression in vascular endothelial cells Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1539 - H1545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sander, D. Sander, H. Audebert, and R. L. Haberl Systemic Inflammatory Response Depends on Initial Stroke Severity but Is Attenuated by Successful Thrombolysis * Response Stroke, February 1, 2005; 36(2): 232 - 232. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, J. L. Anderson, R. O. Cannon III, Y. Y. Fadl, W. Koenig, P. Libby, S. E. Lipshultz, G. A. Mensah, P. M Ridker, and R. Rosenson CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Clinical Practice Discussion Group Circulation, December 21, 2004; 110(25): e550 - e553. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Diomedi, A. Pietroiusti, M. Silvestrini, B. Rizzato, L. M. Cupini, F. Ferrante, A. Magrini, A. Bergamaschi, A. Galante, and G. Bernardi CagA-positive Helicobacter pylori strains may influence the natural history of atherosclerotic stroke Neurology, September 14, 2004; 63(5): 800 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Audebert, M. M. Rott, T. Eck, and R. L. Haberl Systemic Inflammatory Response Depends on Initial Stroke Severity but Is Attenuated by Successful Thrombolysis Stroke, September 1, 2004; 35(9): 2128 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lombardo, L. M. Biasucci, G. A. Lanza, S. Coli, P. Silvestri, D. Cianflone, G. Liuzzo, F. Burzotta, F. Crea, and A. Maseri Inflammation as a Possible Link Between Coronary and Carotid Plaque Instability Circulation, June 29, 2004; 109(25): 3158 - 3163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Napoli and A. Arakelyan POEMS Syndrome, Fibrinogen, and Ischemic Stroke: A Critical Point of View Arch Neurol, January 1, 2004; 61(1): 155 - 155. [Full Text] [PDF]
|
|
|
|
|
|
P.J. Kelly, J.P. Kistler, V.E. Shih, R. Mandell, N. Atassi, M. Barron, H. Lee, S. Silveira, and K.L. Furie Inflammation, Homocysteine, and Vitamin B6 Status After Ischemic Stroke Stroke, January 1, 2004; 35(1): 12 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli and F. Papa Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke Stroke, December 1, 2003; 34(12): 2922 - 2929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Napoli and F. Papa Association Between Blood Pressure and C-Reactive Protein Levels in Acute Ischemic Stroke Hypertension, December 1, 2003; 42(6): 1117 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.M. Hirschfield and M.B. Pepys C-reactive protein and cardiovascular disease: new insights from an old molecule QJM, November 1, 2003; 96(11): 793 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Dalton, W. H. Hoffman, G. G. Passmore, and S. L. A. Martin Plasma C-Reactive Protein Levels in Severe Diabetic Ketoacidosis Ann. Clin. Lab. Sci., October 1, 2003; 33(4): 435 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli Editorial Comment--C-Reactive Protein and Vascular Risk in Stroke Patients: Potential Use for the Future Stroke, October 1, 2003; 34(10): 2468 - 2470. [Full Text] [PDF]
|
|
|
|
|
|
J. F. Arenillas, J. Alvarez-Sabin, C. A. Molina, P. Chacon, J. Montaner, A. Rovira, B. Ibarra, and M. Quintana C-Reactive Protein Predicts Further Ischemic Events in First-Ever Transient Ischemic Attack or Stroke Patients With Intracranial Large-Artery Occlusive Disease Stroke, October 1, 2003; 34(10): 2463 - 2468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli Editorial Comment--How to Search for the Role of Genetic Polymorphisms in Stroke: Theory Versus Practice Stroke, August 1, 2003; 34(8): 1869 - 1870. [Full Text] [PDF]
|
|
|
|
|
|
D. Acalovschi, T. Wiest, M. Hartmann, M. Farahmi, U. Mansmann, G. U. Auffarth, A. J. Grau, F. R. Green, C. Grond-Ginsbach, and M. Schwaninger Multiple Levels of Regulation of the Interleukin-6 System in Stroke Stroke, August 1, 2003; 34(8): 1864 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Denny Jr Prediction of Restenosis after Carotid Artery Stent Implantation Radiology, May 1, 2003; 227(2): 316 - 318. [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli and F. Papa C-Reactive Protein and Blood Pressure in the Acute Phase After an Ischemic Stroke Stroke, April 1, 2003; 34(4): 839 - 839. [Full Text] [PDF]
|
|
|
|
|
|
J. Kennedy and A.M. Buchan Ever Decreasing Circles: Advances in Antiplatelet Therapy and Anticoagulation Stroke, February 1, 2003; 34(2): 348 - 350. [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli, F. Papa, K. Winbeck, and D. Sander Clinical Use of C-Reactive Protein for Prognostic Stratification in Ischemic Stroke: Has the Time Come for Including It in the Patient Risk Profile? Stroke, February 1, 2003; 34(2): 375 - 376. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Pearson, G. A. Mensah, R. W. Alexander, J. L. Anderson, R. O. Cannon III, M. Criqui, Y. Y. Fadl, S. P. Fortmann, Y. Hong, G. L. Myers, et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association Circulation, January 28, 2003; 107(3): 499 - 511. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurth, J. M. Gaziano, K. Berger, C. S. Kase, K. M. Rexrode, N. R. Cook, J. E. Buring, and J. E. Manson Body Mass Index and the Risk of Stroke in Men Arch Intern Med, December 9, 2002; 162(22): 2557 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Marquardt, A. Ruf, U. Mansmann, R. Winter, M. Schuler, F. Buggle, H. Mayer, and A. J. Grau Course of Platelet Activation Markers After Ischemic Stroke Stroke, November 1, 2002; 33(11): 2570 - 2574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Winbeck, H. Poppert, T. Etgen, B. Conrad, and D. Sander Prognostic Relevance of Early Serial C-Reactive Protein Measurements After First Ischemic Stroke Stroke, October 1, 2002; 33(10): 2459 - 2464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Iyigun, M. Di Napoli, and F. Papa C-Reactive Protein in Ischemic Stroke * Response Stroke, September 1, 2002; 33(9): 2146 - 2147. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Need to Test the Arterial Inflammation Hypothesis Circulation, July 2, 2002; 106(1): 136 - 140. [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli and F. Papa Inflammation, Hemostatic Markers, and Antithrombotic Agents in Relation to Long-Term Risk of New Cardiovascular Events in First-Ever Ischemic Stroke Patients Stroke, July 1, 2002; 33(7): 1763 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Steinke and S. C. Ley Lacunar Stroke Is the Major Cause of Progressive Motor Deficits Stroke, June 1, 2002; 33(6): 1510 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Loftus and M. Thompson The role of matrix metalloproteinases in vascular disease Vascular Medicine, May 1, 2002; 7(2): 117 - 133. [Abstract] [PDF]
|
|
|
|
|
|
P. B. Gorelick Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review Stroke, March 1, 2002; 33(3): 862 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli and F. Papa Inflammation, Statins, and Outcome After Ischemic Stroke Stroke, October 1, 2001; 32 (10): 2446 - 2447. [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli, G. Xi, R. F. Keep, Y. Hua, and J. T. Hoff Systemic Complement Activation in Ischemic Stroke Response Stroke, June 1, 2001; 32 (6): 1443 - 1448. [Full Text] [PDF]
|
|